Skip to main content
Premium Trial:

Request an Annual Quote

New Zealand Patent Office to Issue Patent on Marina UNA Technology

Premium

Marina Biotech this week announced that the Intellectual Property Office of New Zealand said it will grant the company a patent covering its unlocked nucleobase analog technology.

The accepted patent application, No. 580712, specifically claims “multiple sequence-independent and length-independent nucleic acid constructs having one or more unlocked nucleobase analogs,” according to Marina. The constructs include RISC- and Dicer-length siRNAs, microRNA mimetics and antagonists, and single-stranded oligos.

UNAs comprise an acyclic ribonucleoside analog in which the bond between C2' and C3' atoms is broken. The resultant change in sugar structure is designed to make the analog flexible and reduce the binding affinity of an siRNA's strands.

"This allowed patent is part of our global UNA patent portfolio providing broad and comprehensive protection for multiple distinct UNA-containing nucleic acid constructs all of which can modulate gene expression through distinct cellular mechanisms including RNAi, mRNA translational inhibition, steric blocking, or microRNA pathways,” Marina President and CEO Michael French said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.